OPEN APP
Home >Science >Health >Serum Institute denies side effects claim, says Covishield 'safe and immunogenic

After a Chennai-based man claimed that he suffered neurological and psychological side effects taking a shot of Covid-19 vaccine Covishield during the human trial being conducted by Serum Institute of India's (SII), the Pune-based company said there was no correlation between the two. In a social media post, the institute said, "Covishield is safe & immunogenic, the incident with the Chennai volunteer no way induced by the vaccine."

Addressing concerns related to the serious adverse event reported by a volunteer in Chennai, SII said, "Serum Institute of India is sympathetic with the volunteer's medical condition. However, we would like to clarify that all the requisite regulatory and ethical processes and guidelines were followed diligently and strictly. The concerned authorities were informed and the Principal Investigator, DSMB and the Ethics Committee independently cleared and reckoned it as a non-related issue to the vaccine trial. Post which we submitted all the reports and data related to the incident to the DCGI. It is only after we cleared all the required processes that we continued with the trials."

SII further stated that the vaccine won’t be released for mass use unless it is proven immunogenic, and safe. "The legal notice was sent to safeguard the reputation of the company which is being unfairly maligned: Serum Institute of India," said SII.

SII is conducting clinical trials of AstraZeneca-Oxford's Covid-19 vaccine candidate in India. Currently, the phase-3 clinical trial of Covaxin is being conducted across India involving 26,000 participants. The vaccine will be produced in the Biosafety Level 3 production facility of the company.

The vaccine candidate, Covishield, is being developed by the UK's Oxford University and US pharma giant AstraZeneca. The SII is a manufacturing partner for the vaccine.





Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
×
Edit Profile
My ReadsRedeem a Gift CardLogout